BR112022005995A2 - Variantes do domínio ch1 projetadas para emparelhamento preferencial de cadeia leve e anticorpos multispecíficos compreendendo as mesmas - Google Patents

Variantes do domínio ch1 projetadas para emparelhamento preferencial de cadeia leve e anticorpos multispecíficos compreendendo as mesmas

Info

Publication number
BR112022005995A2
BR112022005995A2 BR112022005995A BR112022005995A BR112022005995A2 BR 112022005995 A2 BR112022005995 A2 BR 112022005995A2 BR 112022005995 A BR112022005995 A BR 112022005995A BR 112022005995 A BR112022005995 A BR 112022005995A BR 112022005995 A2 BR112022005995 A2 BR 112022005995A2
Authority
BR
Brazil
Prior art keywords
domain variants
domain
chain
same
light chain
Prior art date
Application number
BR112022005995A
Other languages
English (en)
Inventor
Arvind Sivasubramanian
Eric Krauland
Kevin Schutz
Michaela Helble
Paul Widboom
Original Assignee
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adimab Llc filed Critical Adimab Llc
Publication of BR112022005995A2 publication Critical patent/BR112022005995A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N19/00—Methods or arrangements for coding, decoding, compressing or decompressing digital video signals
    • H04N19/10—Methods or arrangements for coding, decoding, compressing or decompressing digital video signals using adaptive coding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Signal Processing (AREA)
  • Multimedia (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

variantes do domínio ch1 projetadas para emparelhamento preferencial de cadeia leve e anticorpos multispecíficos compreendendo as. mesmas. variantes de domínio ch1 manipuladas para ligação preferencial a um domínio kappa cl ou a um domínio lambda cl, bem como polipeptídeos, por exemplo, cadeias pesadas de anticorpos ou anticorpos, compreendendo tais variantes de domínio ch1 manipuladas e composições farmacêuticas compreendendo tais variantes de domínio ch1 e/ou tais polipeptídeos e métodos para fazer e usar tais variantes de domínio ch1 são fornecidas. as variantes do domínio ch1 minimizam o emparelhamento incorreto de cadeia pesada-cadeia leve e promovem o emparelhamento cognato de cadeia pesada-cadeia leve, melhorando assim a geração de anticorpos multiespecíficos, por exemplo, biespecíficos. também são fornecidos métodos para fazer bibliotecas de variantes de domínio ch1 e métodos para identificar uma ou mais variantes de domínio ch1.
BR112022005995A 2019-09-30 2020-09-30 Variantes do domínio ch1 projetadas para emparelhamento preferencial de cadeia leve e anticorpos multispecíficos compreendendo as mesmas BR112022005995A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962908367P 2019-09-30 2019-09-30
PCT/US2020/053482 WO2021067404A2 (en) 2019-09-30 2020-09-30 Ch1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same

Publications (1)

Publication Number Publication Date
BR112022005995A2 true BR112022005995A2 (pt) 2022-06-21

Family

ID=75338609

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005995A BR112022005995A2 (pt) 2019-09-30 2020-09-30 Variantes do domínio ch1 projetadas para emparelhamento preferencial de cadeia leve e anticorpos multispecíficos compreendendo as mesmas

Country Status (11)

Country Link
US (1) US20230265134A1 (pt)
EP (1) EP4021939A4 (pt)
JP (1) JP2022550172A (pt)
KR (1) KR20220107163A (pt)
CN (1) CN114846027A (pt)
AU (1) AU2020357944A1 (pt)
BR (1) BR112022005995A2 (pt)
CA (1) CA3152460A1 (pt)
IL (1) IL291728A (pt)
MX (1) MX2022003744A (pt)
WO (1) WO2021067404A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111315768A (zh) 2017-09-07 2020-06-19 库尔生物制药有限公司 具有缀合位点的t细胞调节性多聚体多肽及其使用方法
EP4370545A1 (en) * 2021-07-12 2024-05-22 Genentech, Inc. Structures for reducing antibody-lipase binding
WO2023079102A2 (en) * 2021-11-05 2023-05-11 Alligator Bioscience Ab Novel peptides
WO2023169559A1 (en) * 2022-03-11 2023-09-14 Elpiscience Biopharma , Ltd. Modified antibodies and uses thereof
WO2024061223A1 (zh) * 2022-09-20 2024-03-28 普米斯生物技术(珠海)有限公司 抗体及其在抗肿瘤中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005092925A2 (en) * 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
AU2014225661A1 (en) * 2013-03-06 2015-09-10 Merrimack Pharmaceuticals, Inc. Anti-c-Met tandem Fc bispecific antibodies
EP2966085A1 (en) * 2014-07-11 2016-01-13 Boehringer Ingelheim International GmbH Antibody IgG1 with a modified heavy chain constant region
KR20240093813A (ko) * 2015-04-24 2024-06-24 제넨테크, 인크. 다중특이적 항원-결합 단백질
WO2018016881A1 (ko) * 2016-07-19 2018-01-25 (주)아이벤트러스 이중 특이성 단백질 및 이의 제조 방법

Also Published As

Publication number Publication date
IL291728A (en) 2022-05-01
CN114846027A (zh) 2022-08-02
EP4021939A4 (en) 2023-11-22
EP4021939A2 (en) 2022-07-06
KR20220107163A (ko) 2022-08-02
CA3152460A1 (en) 2021-04-08
WO2021067404A2 (en) 2021-04-08
US20230265134A1 (en) 2023-08-24
JP2022550172A (ja) 2022-11-30
MX2022003744A (es) 2022-07-21
AU2020357944A1 (en) 2022-03-31
WO2021067404A3 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
BR112022005995A2 (pt) Variantes do domínio ch1 projetadas para emparelhamento preferencial de cadeia leve e anticorpos multispecíficos compreendendo as mesmas
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
EA201990331A1 (ru) Мультиспецифические антигенсвязывающие белки и способы их применения
CO2019009432A2 (es) Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap.
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
EA201890866A1 (ru) Связывающие молекулы, которые ингибируют рост рака
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
CO2019007046A2 (es) Moléculas de unión a antígeno biespecíficas que comprenden el clon 20h4.9 anti-4-1bb
CO2021003900A2 (es) Moléculas de unión a antígeno biespecíficas que comprenden el clon 212 anti-fap
BR112021026890A2 (pt) Composições de anticorpo para interromper biofilmes
BR112021021754A2 (pt) Cicloalquilas substituídas como moduladoras da via de estresse integrada
CL2008003779A1 (es) Anticuerpo bivalente bioespecifico que consta de las cadenas ligeras y pesadas de anticuerpos que se une a un primer y segundo antigeno, en el que los dominios constantes cl y ch1 y variables vl y vh, de las cadenas del anticuerpo para el segundo antigeno, se reemplazan entre si; metodo de producción; composición farmaceutica.
BR112017003236A2 (pt) anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica
AR060871A1 (es) Union de polipeptidos con supercontigos optimizados
EA201000717A1 (ru) Молекулы и способы, предназначенные для модуляции компонента системы комплемента
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
EA201100869A1 (ru) Противоопухолевые комбинации, содержащие специфически распознающие cd38 антитела и циклофосфамид
EA201791527A1 (ru) Биспецифические антитела против плазменного калликреина и фактора xii
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
UY30776A1 (es) Anticuerpos cd44
EA200970909A1 (ru) Новый антиген, ассоциированный с новообразованными сосудами опухолевых метастазов
AR076018A1 (es) Anticuerpos multiespecificos especialmente biespecificos
CR10529A (es) Composiciones y metodos para la modulacion del desarrollo vascular